Compare Compass Inc. Class A Common Stock (COMP) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Compass Inc. Class A Common Stock vs Cytokinetics Inc — how do they compare? Compass Inc. Class A Common Stock trades at $9.52 (market cap $7.05B), while Cytokinetics Inc trades at $62.02 (market cap $8.50B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Compass Inc. Class A Common Stock is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Compass Inc. Class A Common Stock for 0 Days and Cytokinetics Inc for 19 Days on average.
| COMP | CYTK | |
|---|---|---|
Market Cap | $7.05B | $8.50B |
Volume | 15,310,192 | 2,395,556 |
Sector | Real Estate | Health |
52-Week High | $13.58 | $87.26 |
52-Week Low | $6.68 | $54.76 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $10.47B | $8.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Cytokinetics (CYTK) trades at $62.01, up 1.08% on the day, amid mixed technical signals with a bearish overall trend but bullish oscillators. The company shows strong analyst support with 97% buy ratings and a $112.50 consensus price target, though fundamentals remain challenged with a -1,321% net income margin and significant losses. Recent positive Phase 3 trial results for aficamten in non-obstructive HCM and commercial expansion of MYQORZO provide growth catalysts.
The stock presents high-risk, high-reward potential with Wall Street optimism contrasting with current financial losses. Key opportunities include successful drug commercialization and pipeline advancements, while risks involve execution challenges, competitive pressure from Bristol Myers Squibb's Camzyos, and sustained cash burn. The substantial upside to analyst targets reflects expectations for future revenue growth from heart failure treatments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Compass Inc. Class A Common Stock
Compass is a technology-enabled residential real estate company. Its platform provides agents with tools for customer relationships, marketing, client service, and transactions, alongside brokerage, title, escrow, and mortgage services.
Read more on COMP →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
